(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) By Mark Long Here's what's making health news this morning: Texas Eyes Change in Stem-Cell Rules (WSJ): The state's medical board will vote today on rules that would make it easier for physicians to offer treatments using adult stem cells. Bayer Said to Pay $110 Million in Yaz Birth-Control Cases (Bloomberg News): People familiar with the agreements told Bloomberg that the German drug maker will settle about 500 lawsuits claiming the pills caused blood clots. States Seek Curb on Patient Bills for Costly Drugs (New York Times): Lawmakers in at least 20 states have introduced bills to limit the amount patients with diseases that are expensive to treat have to pay out of pocket. Medicare to Settle Hospital Reimbursement Dispute (Los Angeles Times): The Centers for Medicare and Medical Services agreed to settle the dispute with about 2,200 hospitals over an error in reimbursement rates. Sexual Side Effects Added to Merck Drug Labels (Reuters): U.S. health regulators said the labels for a baldness treatment, Propecia, and one for enlarged prostate, Proscar, will note side effects that lasted after use of the drugs ended. Hospitals Drop Plan for Merger (WSJ): St. Anthony Medical Center and Rockford Memorial Hospital in Rockford, Ill., bowed to pressure from the FTC, which said a deal would make a local monopoly. Novartis: MS Pill Gilenya Patient Develops Rare Brain Disease (Dow Jones Newswires): The multiple-sclerosis patient, diagnosed with often-fatal progressive multifocal leukoencephalopathy, had also been previously treated with another MS drug, Novartis said. -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.